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ABSTRACT 
Neuroblastoma is the most common and aggressive extracranial solid tumor during 
childhood. MYCN-amplification is found in approximately 25 % of all neuroblastoma cases, 
and is defined as high-risk disease. Development of novel therapeutic approaches focused on 
MYCN targeting are essential for increased survival these children. The MYC family of 
oncoproteins consists of transcriptional factors involved in many normal cellular processes. 
Abnormal expression of MYC is associated with 70 % of human cancers and correlates with 
an aggressive undifferentiated phenotype, chemotherapy resistance and poor clinical 
prognosis.  
Targeting MYCN by small molecular weight molecules remains a challenge. In paper I we 
established that one known c-MYC targeting compound, the small chemical molecule 10058-
F4, is also a potent MYCN inhibitor. 10058-F4 treatment increased cell death and neuronal 
differentiation in MYCN-amplified neuroblastoma cells and prolonged survival in mice. 
Interestingly, we found that MYCN inhibition resulted in changes in expression of metabolic 
proteins, in accumulation of intracellular lipid droplets and demonstrated that this is due to 
mitochondrial dysfunction. Our data reported in paper I strongly suggests that MYCN 
regulated metabolic processes may contribute to the aggressiveness of neuroblastoma. 
In paper II we applied several approaches to further investigate the MYCN-mediated 
metabolic alterations in neuroblastoma. The combination of mass spectrometry based 
proteomics and transcriptome data analysis highlighted key metabolic enzymes involved in 
energetic pathways of cancer cells. The functional metabolic measurements supported the 
data analysis and demonstrated that MYCN not only enhanced the glycolytic capacity of 
neuroblastoma cells, but also increased mitochondrial respiration. The data presented in 
paper II suggests that MYCN-amplification is associated with a high-energetic metabolic 
phenotype. Importantly, we demonstrated that targeting of fatty acid oxidation resulted in 
potentiated neuronal differentiation, decreased viability of MYCN-amplified neuroblastoma 
as well as decreased tumor burden in vivo in a neuroblastoma xenograft model. 
Our previous findings highlighted an important role of fatty acid metabolism in MYCN-
amplified neuroblastoma. In paper III we used specific inhibitors and demonstrated that 
targeting of de novo fatty acid synthesis in MYCN-amplified neuroblastoma cells resulted in 
increased mitochondrial dysfunction and glycolytic flux. In addition, we observed that 
MYCN downregulation and neuronal differentiation are consequences of inhibiting de novo 
synthesis of fatty acids in neuroblastoma cells.  
In paper IV we demonstrated that the miR-17~92 cluster, which is upregulated by MYCN, 
suppresses neuronal differentiation via targeting of the nuclear hormone receptor family in 
neuroblastoma. Importantly, we showed that MYCN inhibition leads to increased expression 
of the glucocorticoid receptor, which is accompanied by decreased levels of members of the 
miR-17~92 clusters and elevated expression of the neural differentiation markers TrkA, 
SCG2 and TH. Furthermore, increased GR expression followed after MYCN downregulation 
and decreased tumor burden was observed in a pre-clinical NB model following combined 
MYC inhibition and activation of glucocorticoid signaling. 
Together the data generated in our laboratory and included in the present thesis demonstrates 
that targeting of MYCN and MYCN-controlled metabolic processes may provide an 
attractive basis for development of novel therapeutic approaches for childhood 
neuroblastoma. 
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1 INTRODUCTION 
1.1 CANCER 
Cancer is a very complex disease comprised of more than 200 types of tumors. It is 
characterized by uncontrolled cell growth and unlimited metastasis to different types of 
tissues and organs, which is a major cause of death from cancer1. The development of the 
disease involves the dysfunction of numerous biological systems and processes including the 
immune system, metabolism, DNA repair, cell proliferation and cell death. Cancer is a key 
health problem and the leading cause of death worldwide2,3. 
1.1.1 Oncogenes and tumor suppressors 
Figure 1. A schematic overview of proto-oncoproteins in cell-growth regulation. Proto-
oncoproteins promote the cell cycle and are involved in different signal cascades, which regulate 
cellular proliferation and differentiation.  
Proto-oncogenes are involved in regulation and control of cell growth, differentiation and 
apoptosis in normal cells. The proto-oncogenes which display abnormal expression level or 
have gain-of-function mutations and are able to promote cancerogenesis are termed 
oncogenes. They encode transcription factors, signal transducers and chromatin remodelers4. 
The functions of oncogenes and their products are very important for cell transformation, 
cancer cell progression and tumor biomass production5,6 (Figure 1). Cytoplasmic proto-
oncogenes encode growth factors, growth-factor receptors and different protein kinases. For 
instance, RAS family encodes G proteins. Nuclear proto-oncogenes encode transcriptional 
factors, such as MYC family. 
Tumor suppressor genes are another group of genes which are involved in the control of the 
cell cycle, DNA repair, apoptosis as well as other cellular processes and have a crucial role in 
cancerogenesis. One copy of a tumor suppressor gene is enough to regulate cellular 
proliferation, but loss-of-function mutation of both alleles promotes cancer development. The 
RB (retinoblastoma susceptibility), PTEN (phosphatase and tensin homolog) and p53 are 
examples of tumor suppressor genes important for control of cell proliferation6.  
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1.1.2 Hallmarks of cancer 
The network of processes involved in cancer initiation, development and progression was 
summarized and defined as the Hallmarks of cancer by Hanahan and Weinberg7,8. The 
highlighted processes are: (1) continuous proliferative signaling (cancer cells enhance their 
own growth), (2) deviation of response to growth suppressors (cancer cells resist anti-growth 
signaling), (3) resistance to programmed cell death/apoptosis, (4) limitless multiplication 
potential, (5) angiogenesis, (6) metastasis, (7) avoiding elimination by the immune system 
and (8) altered metabolism (Figure 2). 
One of the crucial features of cancer is the ability to maintain constant proliferation. The 
process of cell growth is strictly controlled in normal tissues by signals from the 
microenvironment, which enhance or suppress cell proliferation. An increase of enhancer 
and/or deficiency of suppressors results in an uncontrolled growth rate in cancer cells. During 
the last decade many chemical compounds targeting specific genes and/or proteins involved 
in facilitating a particular hallmark of cancer have been developed and are in clinical trials or 
in clinical use (Figure 2). 
 
Figure 2. Therapeutic approaches of targeting of the Hallmarks of Cancer. Drugs and small chemical 
compounds, which target specific tumorigenic pathways and which approved for clinical trials are 
indicated. (Reprinted from Hanahan and Weinberg, Cell 2011 with a kind permission from Elsevier). 
1.1.3 MicroRNAs in cancer 
The microRNAs (miRNAs) were discovered in 1993 during studies on Caenorhabditis 
elegans. They are defined as small non-protein-coding RNAs that regulate protein expression 
by binding to matching sequences in the 3’-untranslated region messenger RNAs (mRNA), 
which results in the inhibition of mRNA stability9. Approximately 2,800 human miRNAs are 
available in public sources. In 2015, Rigoutsos’ research group from Thomas Jefferson 
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University in Philadelphia identified 3,707 novel miRNAs, many of which are human-
specific10. Around half of the known miRNAs are organized in clusters, including two or 
more members. MiRNA clusters have similar expression patterns and impact transcription of 
genes as polycistronic transcripts11. The study of the connection between miRNAs and their 
predicted targets is a very complex, since a single miRNA may affect nearly 100 mRNAs and 
each mRNA in turn may be targeted by several miRNAs12.  
MiRNAs are involved in a broad spectrum of biological processes, including carcinogenesis, 
through control of transcription and expression of mRNAs. At present, miRNAs targets in 
cancer have been associated with tumor proliferation, altered metabolism, metastasis, 
dysfunctional immune system, differentiation and angiogenesis13,14. There are several 
mechanisms of deregulation of miRNAs expression in human malignancies15.  
Altered expression of miRNAs correlates with genomic abnormalities such as amplification 
and translocation16. Epigenetic factors can also influence the level of miRNAs, and 
transcription factors can also induce oncogenic and/or inhibit tumor suppressive miRNAs17-
19. Moreover, several miRNA families exhibit tumor suppressor functions; for instance, miR-
15 and miR-16-1 and inhibit expression of anti-apoptotic proteins in different types of 
cancer20. 
MiRNAs play significant roles not only in cancer biology, but also in oncology. Cancer 
associated small non-coding RNAs can be detected in the biological fluids and used as 
biomarkers for disease diagnosis, monitoring and prognosis21. Moreover, it has been reported 
that the normalization of deregulated expression of miRNAs decreases tumor growth in 
vivo.22 Re-expression of some miRNAs by treatment with small chemical molecules may be a 
possible basis for development of novel anti-cancer therapies.  
1.1.4 Nuclear hormone receptors superfamily 
The nuclear hormone receptor (NHR) superfamily includes 48 human and 49 mouse genes, 
including steroids, retinoids, thyroids and vitamin D323,24. The members of the superfamily 
are activated by numerus different ligands25. They bind to specific DNA sequences and are 
able to activate or suppress transcription. The activity of NHRs requires two steps: interaction 
with the corresponding hormone, followed by binding of the receptor dimers to DNA to 
regulate transcription. NHRs are involved in the regulation of development and 
differentiation of skin, the constant regulation of reproductive tissues and, most importantly, 
the members of the NHR family play a role in the regulation of neuronal differentiation26.  
1.1.5 Childhood malignancies versus adult cancers 
Cancerogenesis is associated with old age and is more common in older individuals than in 
young27. However, cancer is the most common cause of death by disease during childhood 
(aged birth-14 years) worldwide. There are more than 150 cases per million in Europe each 
year28. In the majority of cases the cause of tumorigenesis is unknown. Quite often the types 
of tumors that develop in infants are different from the adult cancers. However, childhood 
cancers, as well as adult malignancies, may display deregulation of oncoproteins, such as 
MYC and loss of function of tumor suppressor genes, for instance p53 mutations. Pediatric 
malignancies are not associated with life style and/or impact of environment as many cancers 
in adults, but these factors may influences the children before the birth during pregnancy29. 
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Generally, childhood tumors are a result of genetic alterations in cells, which occur very 
early, often before birth. But, according to a recent scientific report, 90 % of all human 
cancers are the results of errors in DNA replication30. Cancers in infants are characterized by 
an aggressive phenotype and are usually diagnosed at more advanced stages compared to 
adult disease. Pediatric and adult cancers differ not only in development, genetic background 
and diagnosis but also in therapeutic approaches, effects and consequences of therapy31. 
Chemotherapy, surgery and radiation therapy are the main therapeutic approached in 
pediatric oncology. Chemotherapy used in the treatment of cancers, targets cells with the 
highest growth rate and has more severe side effects in children than in adults, since their 
bodies are still actively developing. The majorities of side effects of anti-cancer treatments 
occur during or just after the therapy and go away in a short time. Unfortunately, anti-cancer 
therapy may lead to late side effects, such as delayed growth in children, cognitive problems 
as well as the formation of other types of cancer later on in life. Late side effects constitute a 
major problem in pediatric oncology32. 
1.2 NEUROBLASTOMA 
Neuroblastoma (NB) is a rare embryonic neural tumor, but one of the most common and 
deadliest extracranial solid tumors of childhood. It is accounting for approximately 7 % of all 
pediatric malignancies and 15 % of childhood cancer deaths33,34. In Sweden 15-20 new cases 
are diagnosed per year. The majority of NB cases are diagnosed in infants under the age 5 
years. Approximately 70% of all cases are patients with high-risk NB, which is usually 
characterized by genetic alterations and the metastasis. Only less than a half of these patients 
can be cured.  
1.2.1 Origin of Neuroblastoma  
Focusing on the cells of origin of neuroblastoma is important for understanding malignancy. 
The neural crest is present only during embryogenesis (Figure 3) and maturates to different 
cell types, such as glia, peripheral and enteric neurons, melanocytes, cells of craniofacial 
skeleton, adrenal medulla and Schwann cells35. The adrenal medulla is the inner part of 
adrenal gland and ganglion of the sympathetic nervous system. NB originates from primitive 
neuroepithelial cells of the neural crest (Figure 3), and can develop anywhere in the 
sympathetic nervous system. The majority of the primary tumors occurs in the adrenal 
glands, sympathetic ganglia and is commonly found in the abdomen and neck36,37. 
High expression of the proto-oncogene MYC during normal sympathoadrenal development is 
essential for neural crest migration and growth38,39. In differentiating sympathetic neurons, 
MYCN level decreases40. In vivo studies demonstrated that overexpressing MYCN in 
sympathoadrenal cells initiates neuroblastoma development41. Th-MYCN transgenic mice 
spontaneously develop neuroblastoma as a result of high expression of MYCN, controlled by 
the rat tyrosine hydroxylase42. 
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Figure 3. A schematic overview of neural crest development and migration. Migration of 
sympathoadrenal precursor from the neural crest and their specification depend on transmembrane 
signals. (Adapted from Marshall, G. M. et al, Nat. Rev. Cancer 2014). 
1.2.2 Differentiation in neuroblastoma 
Neuroblastoma tumors are characterized by three types of cells, based on their morphological 
and biochemical properties. N-type - neuroblastic cells malignant cells with neuronal 
properties; S-type – cells with non-neuronal phenotype; I-type – highly malignant cancer 
stem cells, are able to differentiate to S- or N- type43. Histology based on NB tumor cells sub-
type is used in the clinic as an outcome prognosis and it has been shown that undifferentiated 
tumors with poor prognosis and tumors with neuron-like differentiated cells demonstrate 
favorable prognosis44.  
MYCN plays a major role in NB differentiation, it is critical for initiation of neural crest 
differentiation, but high MYCN expression associates with an undifferentiated phenotype in 
NB. Furthermore, high expression of MYCN correlates with enhanced expression of the 
tropomyosin receptor kinase B (TrkB) neurotrophin receptor, which associates with an 
aggressive NB phenotype. At the same time, MYCN-amplification suppresses the tyrosine 
receptor kinase A (TrkA) nerve growth factor receptor, which is marker for good prognosis in 
NB patients45. TrkA expression is critical during development of symphatethetic neurons. 
Additionally, MYC enhances the level of the miR-17~92 cluster, which results in suppression 
of cellular differentiation via downregulation of the nuclear hormone receptor family14,46. 
Direct or indirect targeting of MYCN result in upregulation of estrogen receptor α, TrkA, 
glucocorticoid receptor and induced neural outgrowth of NB cells in vitro and decreased 
tumor burden in vivo.  
The capacity of NB cells to differentiate along the sympathoadrenal linage is being used for 
the development of the novel therapeutic approaches in NB. All trans-retinoic acid (ATRA), 
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a derivative of vitamin A is used in the clinic and induces differentiation and prolongs 
survival of high-risk NB47. Importantly, it was demonstrated that ATRA also inhibits MYCN 
in MYCN-amplified NB, which potentiates neuronal differentiation. Furthermore, ATRA 
decreases the proliferation rate and tumor size in vivo48.  
1.2.3 Neuroblastoma is a heterogeneous disease 
Neuroblastoma is a highly heterogenic disease and thus can be found in different forms: from 
localized tumors, which can be treated by surgery to metastatic types with high resistance to 
therapy and poor prognosis. Also, NB includes a very special group – spontaneous regressing 
tumors49,50. The international neuroblastoma risk group (INRG) is a pre-treatment 
classification system. INRG includes 4 different group of cancer: very low-risk, low risk, 
intermediate-risk and high-risk. Very low-risk and low-risk groups include NB cases with 
localized primary tumors without MYCN-amplification and 11q chromosome aberration and 
can be curable with surgery and/or chemotherapy. Besides, this group includes patients with 
spontaneously regressing tumors. Intermediate-risk NB includes cases with tumors that 
spread to the lymph nodes, but with negative MYCN status and, cannot be treated by surgery 
alone, chemotherapy is essential. High risk NB is characterized by positive genetic markers 
of poor-prognosis, such as MYCN-amplification, 17q gain and 11q or 1p36 deletion, and ALK 
mutation. MYCN-amplification is found in 30% of high-risk NB and is associated with an 
undifferentiated phenotype and poor outcome. Approximately 2 % of NB patients have a 
family history of disease. Two thirds of these cases have ALK gene activation, which result in 
a high proliferation rate of cancer cells. The therapeutic strategy for high-risk NB is very 
intense and includes several types of treatment51.  
1.2.4 Neuroblastoma and energy metabolism 
Metabolic pathways are dysregulated in the majority of human cancers. The number of 
studies focused on the investigation of mechanisms behind metabolic alterations in adult 
cancers progressively increase, however in contrary very little information about the 
energetic pathways in pediatric malignancies, including NB, is available.  
Only few studies dedicated to metabolic processes in NB have been published. In 2012 
Kusunoki’s research group from Mie University, Japan demonstrated that elevated expression 
of GLUT1 is associated with poor prognosis in patients and that glycolysis inhibitors may be 
used as a possible treatment option for NB52. Unfortunately, the difference between MYCN-
amplified (MNA) and non MYCN-amplified (NMNA) NB was not investigated. Only 5 from 
47 tumor samples were MNA and only NMNA NB cells used for in vitro assays. In 2010 B. 
Kofler’s research group from the University Hospital Salzburg, Austria studied 14 NB 
samples derived from NMNA undifferentiated tumors and observed a low mitochondrial 
respiratory capacity, but intact mitochondrial architecture in these tumors53. Several early 
reports also demonstrated intact mitochondrial mass and architecture in neuroblastoma 
cells54. 
A recent study demonstrated high level of glucose uptake in low and intermediate risk groups 
of NB using positron emission tomography (PET). PET is an imaging technology for 
monitoring cancer progression, based on uptake of labeled glucose by tumor cells. However, 
the application of PET in high-risk NB was not successful55. High-risk NB associated with 
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MYCN-amplification, which may promote mitochondrial respiration. Increased respiratory 
capacity may explain the significant lower glucose uptake by MYCN-amplified NB tumors.  
1.2.5 Therapeutic approaches in neuroblastoma 
The therapeutic strategy in NB is a very challenging task, which depends on the risk 
classification of disease. Patients with tumors that spontaneously regress do not have severe 
symptoms and do not require therapy, but they are examined frequently and in the case of 
tumor progression treatment is initiated immediately56. Patients with localized primary 
tumors are usually treated by operation alone, and in some cases surgery following 
chemotherapy, which is applied to shrink the tumor size. The combination of restrained 
chemotherapy doses and surgery is used for intermediate-risk NB patients. The children 
diagnosed with high-risk NB go through intense therapy, which includes combination of 
several chemotherapeutic drugs, radiation therapy, surgery, treatment with cis-retinoic acid 
and autologous stem cell transplantation56,57. However, despite this, only half of the patients 
are cured from high-risk NB. Also, patients suffer from drug toxicity and late side effects, 
following the therapy. Therefore, the development of new therapeutic strategy based on 
molecular and genetic characteristics is essential. 
1.3 THE MYC ONCOPROTEIN FAMILY 
The MYC (v-myc avian myelocytomatosis viral oncogene homolog) gene family is composed 
of three known and genetically distinct members: c-MYC, L-MYC and MYCN. They encode 
nuclear phosphoproteins of similar size (Figure 4). The MYC proteins (c-MYC, MYCN and 
MYCL) contain a C-terminal domain consisting of a basic region that can bind to DNA and a 
helix-loop-helix (HLH)-leucine zipper (Zip) domain, which enables interaction with another 
HLH-Zip protein, MAX. All members of the MYC family and some associated proteins (e.g. 
MAX, MXD, MNT) are transcription factors (Figure 4) albeit with weak activity. MYC 
regulates expression of approximately 15% of all human genes through binding to the 
CACGTG Enhancer Box sequences (E-boxes). Upon MYC-MAX binding, the complex 
recruits histone acetyl-transferases (HATs), which increase histone acetylation and thereby 
open up the overall chromatin structure. This allows various transcription factors to interact 
with their respective target genes37. MYC is also able to bind to vertebrate CpG islands 
(CGIs), which also are sites of transcriptional initiation58. Importantly, recently several 
scientific reports demonstrated the ability of MYC to amplify gene expression via 
accumulation in the promoter regions of active genes59,60. Moreover, in 2010 it was shown 
that MYC plays an important role in the RNA polymerase II mediated promoter-proximal 
pausing61. 
The associated proteins MAX network transcriptional repressor (MNT) and MAX gene-
associated protein (MGA) are members of MXD protein family (Figure 4) and able to form 
heterodimers with MAX. Dimerization of MAX with MNT or MGA results in suppression of 
transcription of MYC target genes62. 
Importantly, MYC is able to act not only as a transcriptional activator, but also as a 
transcriptional suppressor. The MYC-interacting zinc finger protein (MIZ-1) binds to initiator 
elements in the core promoter and activates genes transcription via recruiting p300 and NPM. 
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Binding of MYC to MIZ-1 results in the re-localization of MIZ-1 within the nucleus and loss 
of both co-factors p300 and NPM63. 
c-MYC and MYCN share same biological processes, including the dimerization with MAX 
and binding to the same specific sites in DNA, but their pattern of expression differs, which 
could be the major reason for the biological differences between these proteins. c-MYC is 
usually expressed in all proliferating cells, but MYCN is expressed only during development 
processes and its expression is tissue-specific38,64.  
 
 
Figure 4. A schematic overview of the structure of MYC proto-oncoprotein family and associated 
proteins. The MYC proteins contain several preserved domains. Two conserved regions MYC-box I 
and II are in N-terminal transactivation domain (TAD) and three MYC-boxes in the central domain. 
Also, the central domain includes a nuclear localization sequence (NLS). The C-terminal region 
includes a basic helix-loop-helix zipper domain (bHLHZip) and sequence specific DNA-binding basic 
region (B). The associated proteins also contain a bHLHZip domain, basic region and NLS. mSin3-
interaction domain (SID) and MGA contains T-box DNA binding domain (T-domain). 
Taken together, the knowledge about MYC demonstrates its importance for many different 
normal cellular processes such as proliferation, apoptosis and differentiation65(Figure 5). 
Several functions of MYC are discussed below. 
1.3.1 MYC role in the control of cell cycle 
The machinery of cell cycle is synchronized and highly controlled. The cell cycle incudes 
three states, which divided on different phases: resting state - G0 phase (quiescent); interphase 
state - G1, S (synthesis) and G2 phases; division state – mitosis phase. Also, the restriction 
point (R-point) in G1-phase. Cells respond to mitogenic growth signaling in G1-phase until R-
point, after which cells continue to proliferate or stay in G0-phase in non-proliferative stage. 
Each phase during the proliferation is strictly controlled in order to avoid DNA damage66,67. 
The progression of cell cycle through the checkpoints depends on cyclins and cyclin-
dependent kinases (CDKs). The expression of CDKs is stable, while cyclins are synthesized 
and degraded on demand. In the initiation of the G1-phase, in response to mitogenic signals, 
the levels of cyclins D1, D2 and D3 are increased in order to activate CDK4 and CDK6. The 
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cell growth rate increases in G1 phase, in order to facilitate DNA synthesis in S phase the 
expression of transcription factors is promoted by cyclin-CDK complexes. In addition, 
cyclin-CDK complexes reduce the level of S phase inhibitors via ubiquitination followed by 
proteasome degradation66. During S phase cyclin-CDK complexes phosphorylate the proteins 
involved in replication, which is essential for cell cycle progression. For instance, the cyclin 
D-CDK4 complex enables the activation of the E2F transcription factor via phosphorylation 
of retinoblastoma susceptibility (RB) protein68,69. Active E2F initiates transcription of cyclin 
A and cyclin E. The cyclin E-CDK2 complex promotes cell progression to S phase and 
initiates transition between G2 phase and mitosis. In the division state cyclin-CDK complexes 
are crucial for promoting of mitogenic signals66. In the end of mitosis the cyclin B-CDK1 
complex dephosphorylates the RB protein, which is critical for cells to exit the division 
state66. Cyclin dependent kinase inhibitors (CKI) are negative regulators control cell cycle 
during each phase and able to stop its progression if DNA damage occur.  
 
 
Figure 5. MYC controlled cellular processes. MYC involved in normal cellular processes, as well as 
has a great importance in cancerogenesis. (Reprinted from Vita and Henriksson, Seminars in Cancer 
Biology 2006, with a kind permission from Elsevier). 
MYC is expressed in all states of the cell cycle. Elevated expression of MYC promotes 
quiescent cells to enter cell cycle, while downregulation of MYC leads to slow down or stop 
of cell cycle. MYC impacts cell cycle progression via several different mechanisms. It 
directly regulates transcription and induces expression of cell cycle related genes, including 
cyclins, CDKs and E2F genes encoding the E2F transcription factors. Also, via stimulation of 
the CDK activating kinase, MYC promotes activity of cyclin-CDK complexes. Furthermore, 
MYC is able to inhibit CKIs, such as p27 and p21, by blocking their transcription. 
Importantly, MYC upregulates genes encoding the proteins, which are crucial for DNA 
replication, such as cell division cycle 6 (CDC6), chromatin licensing and DNA replication 
factor 1 (CDT1) as well as cell division cycle 45 (CDC45)70. 
The regulation of cell cycle progression is one of the most important MYC functions in 
normal as well as in cancers cells. MYC overexpression in malignant cell promotes cell 
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growth, leading to doubled size and mass, via regulation of cell division, protein synthesis 
and mitochondrial biogenesis. 
1.3.2 MYC triggered apoptosis 
MYC not only controls the cell cycle and cellular growth, but is also a potent promoter of 
programmed cell death - apoptosis. In 1987, Spandidos’ research group from the University 
Medical School, Edinburgh, UK demonstrated that expression of MYC and RAS in rat 
fibroblasts result in an increased apoptosis compared to cells with RAS expression alone71. In 
the early 1990s several research reports showed that abnormal MYC expression enhances the 
sensitivity of premalignant cell to apoptosis72,73. During proliferation cells require growth 
promoting and survival signals. Cell growth promoted by abnormal expression of MYC upon 
withdrawal of survival signals leads to activation of apoptosis73. Importantly, in 1994 MYC 
overexpression was shown to activate the tumor suppressor p53. The activation of p53 results 
in the promotion of pro-apoptotic proteins, such as BAX, NOXA and PUMA, and p21 74. 
MYC targets include the members of BCL-2 family, which is characterized by both pro- and 
anti-apoptotic functions and are localized to the mitochondria. BCL-2 and BCL-XL inhibit the 
pro-apoptotic protein BAX. MYC is able to inhibit expression of BCL-2 and BCL-XL also, 
via the promotion of association of BID with mitochondria, MYC interferes with anti-
apoptotic properties of those proteins75. Furthermore, MYC activates cell death pathways in 
response to tumor necrosis factor (TNF-α). TNF-α induces both pro- and anti-apoptotic 
signals in the cells. Ectopic expression of MYC inhibits anti-apoptotic signaling mediated by 
TNF-α76 
1.3.3 Impact of MYC on cancer cell differentiation 
MYC oncogenes are involved in many cellular processes, including control of differentiation. 
The members of the MYC family are known to be downregulated during differentiation 
processes. Nonetheless, recent studies established that MYC proteins also support 
differentiation in neuronal cells and skin stem cells77.  
Over the last three decades it has been reported that abnormal MYC expression inhibits 
cellular differentiation in the broad spectrum of transformed and primary cell lines. 
Moreover, MYC downregulation is associated with terminal differentiation in cell culture. 
There are several reports suggesting that expression of the MYC dimerization partner MAX 
is reduced during differentiation, leading to decreased expression and activity of MYC78,79. 
MYC inhibits differentiation not only in vitro but also in vivo. Animal studies in mice with 
conditional MYC alleles indicate that the ability to suppress differentiation is crucial for 
MYC-regulated carcinogenesis. Deactivation of MYC results in tumor regression and 
differentiation of cancer cells in transgenic mouse models80,81. Interesting, in hepatocytes the 
transforming activity of MYC depends on the developmental stage of the cells. In a murine 
model of hepatocarcinoma, MYC activation in the mature liver cells induces only cell growth 
and DNA synthesis, however overexpression in embryonic hepatocytes leads to cancer 
initiation82. 
The mechanisms by which MYC regulates proliferation are relatively well-know, in contrast 
to the mechanisms of MYC-controlled differentiation. One of the most accepted hypotheses 
is that MYC alters cell cycle progression to maintain proliferation, which results in decreased 
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differentiation. MYC as a transcription factor decreases expression of numerous 
differentiation-associated genes (TrkA, SCG2) suggesting that MYC may impair 
differentiation independently of cell cycle arrest through alterations in the transcriptome. 
Furthermore, it is well known that MYC targets miRNAs clusters including the miR-17~92 
cluster, which in turn inhibits cellular differentiation14,46.  However, more detailed 
information about MYC-mediated differentiation and its role in human oncogenesis needs be 
studied.  
1.3.4 MYC is a factor of pluripotency 
MYC is one of four transcription factors with the ability to reprogram human somatic cells 
into induced pluripotent stem cells (iPS), which may be used as a unique approach in 
transplantation therapy83,84. In vivo studies showed that iPS cells generated from mouse 
fibroblasts by retroviral induction of four genes (OCT3/4, SOX2, MYC and KLF4) 
demonstrate great similarity to embryonic stem cells. Unfortunately, 20% of the second 
generation of mice derived from an iPS cell line developed tumors, which is associated with 
high MYC expression, while at the same time the level of the other three factors remained 
low85. However, several scientific reports demonstrated that MYC is important, but not 
essential for cell reprograming, while crucial for iPS cells tumorigenicity86. Nevertheless, the 
novel function of MYC may give a clue about its role in control of cancer stem cells81. 
Furthermore, gene set enriched in cancer stem cells are also associated with aggressive and 
undifferentiated phenotype of MYC-driven tumors87,88. On the contrary, a study demonstrated 
that the differentiation of bone marrow hematopoietic stem cells requires an increased MYC 
expression89. MYC’s role in control of cell stemness and tumor initiation has to be 
investigated further.  
1.3.5 Cancer metabolism and MYC 
MYC proteins are involved in regulating nucleotide biosynthesis, ribosome and 
mitochondrial biogenesis and metabolism90. MYC overexpressing tumors are mostly 
aggressive and characterized by high proliferation rate, which requires increased energy 
production it targets genes involved in different metabolic pathways, which results in 
enhanced ATP production and increased levels of substrates essential for cancer cell growth. 
In human Burkitt’s lymphoma, glucose consumption, lactate production and glutamine 
uptake are induced by c-MYC91. MYC enhances expression of key glycolytic enzymes, such 
as the glucose transporter 1 (GLUT1), hexokinase 2 (HK2) and lactate dehydrogenase A 
(LDHA), which lead to increased glucose consumption and lactate production. MYC 
promotes the conversion of glucose to pyruvate and elevates expression of pyruvate 
dehydrogenase kinase 1 (PDK1) to supply oxidative phosphorylation (OXPHOS) with 
pyruvate derived acetyl-CoA91,92.  
The activation of both c-MYC and MYCN promotes glutamine metabolism via up-regulation 
of glutamine transporters93,94. Moreover, MYC promotes expression of mitochondrial 
glutaminase (GLS), the first enzyme in the glutaminolysis pathway, by suppressing miRNAs 
that target GLS. Some MYC overexpressing cell lines are characterized by glutamine- 
depending proliferation, its removal initiates apoptosis93,95. 
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MYC enhances OXPHOS and aerobic glycolysis to stimulate cell cycle progression. 
Furthermore, increased mitochondrial biogenesis and production of lactate and pyruvate 
associated with high MYC expression is essential for the rapid cell cycle entry96. In 
conclusion, MYC targets include the genes involved in the main energy metabolism 
processes (OXPHOS, glycolysis and glutaminolysis) to support cell proliferation. 
1.3.6 The mechanisms of deregulation of MYC expression in cancer 
Low levels of MYC expression is observed during normal proliferation processes97, at the 
same time alterations in MYC expression is found in approximately 70% of human cancers. 
Deregulation of the MYC genes is a consequence of several processes: chromosomal 
translocations, amplifications, single nucleotide polymorphisms in regulatory elements and 
mutations in upstream signaling pathways. Chromosomal translocation mainly occurs in 
leukemia and Burkitt’s lymphomas98,99 while amplifications occur in solid tumors. Enhanced 
expression of oncogenes results in overexpression of MYC proteins and abnormal activation 
of its downstream targets. Proliferation of cancer cells with high MYC level is independent of 
growth-factor promotion, which leads to uncontrolled proliferation, one of the hallmarks of 
cancer. Furthermore, enhanced MYC expression facilitates abnormalities in chromatin 
structure, metabolic processes, ribosomal biogenesis, cell death and angiogenesis7,98,100,101.  
The crucial role of the MYC oncogene may be explained by its impact as a transcription 
factor on a huge set of genes involved in carcinogenesis102. Targets of MYC or “MYC 
signatures” have been identified in a broad range of human malignancies103-105. Importantly, 
these MYC signatures involved in different processes display low overlap, making it difficult 
to generalize MYC’s oncogenic properties based on one set of genes106,107. MYC functions 
not only as a classical transcription factor regulating gene expression though the recruitment 
of the transcription apparatus to promoters, but also by stimulating transcription elongation in 
cancer cells61,108,109. 
Amplification of the MYCN oncogene has been found in approximately 25% of NB cases and 
it is used in the clinic as a genetic marker for poor outcome110. Like c-MYC, MYCN directly 
activates genes that limit proliferation and increase apoptosis.  
1.3.7 Targeting MYC in cancer 
MYC oncogene activation is one of the most common hallmarks of cancer cells. High level of 
MYC expression is involved in cancer initiation and progression, and is often associated with 
an aggressive tumor phenotype and chemotherapy resistance. These factors make MYC an 
attractive therapeutic target. Unfortunately, MYC does not display enzymatic activity, in 
addition the structure of the protein lacks any pocket suitable for small molecule inhibitors. 
There are however several strategies for MYC targeting. Direct inhibitors interrupt MYC-
MAX dimerization and prevent DNA binding as well as increased MYC protein degradation, 
while indirect inhibitors target transcriptional initiation shown to be specific for MYC111,112 
(Figure 6).  
The activity of MYC requires its interaction with its protein partner MAX112, interruption of 
MYC-MAX dimerization is direct approach to target MYC functions. During the last decades 
many small chemical compounds were designed to inhibit MYC-MAX binding113. Two 
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examples of these compounds are 10058-F4 and 10074-G5 that are able disrupt MYC-MAX 
complex and induce cancer cell death and differentiation in vitro114. The small molecule KJ-
Pyr-9 was identified as a MYC inhibitor in the screen of pyridine library. KJ-Pyr-9 prevent 
MYC-MAX complex formation in the cells, very importantly, it has a striking effect on 
cancer cell growth in vivo115. Nevertheless, inhibition MYC activity through interruption 
MYC-MAX heterodimerization requires further studies to improve specificity and 
effectiveness (Figure 6 A). 
One of the effective strategies to disrupt MYC-MAX dimerization is the use of a small (90 
amino acids) protein, Omomyc. It is a dominant negative molecule derived from the 
bHLHZip region of MYC; it is able to form homodimers with MYC to prevent its DNA 
binding and initiating transcriptional activation. At the same time the functions of MYC 
which do not require E-box binding remain unaffected116,117 (Figure 6 A). The studies in 
double transgenic animals with overexpressed MYC and conditionally expressed Omomyc 
demonstrate the capacity of Omomyc to affect cancer cells selectively. Systemic expression 
of Omomyc significantly affects proliferation rate of rapidly dividing cells, while at the same 
time cells death did not increase in normal cells118. 
The small molecule JQ1 was identified in a molecular screen. It prevents transcriptional 
elongation through the binding to acetyl lysine binding site of BET proteins, which result in 
dislocation of BRD4 from chromatin119. Several studies reported the efficiency of JQ1 in 
vitro and in vivo in human malignancies such as triple negative breast cancer, acute myeloid 
leukemia, multiple myeloma and neuroblastoma120-123. The anti-tumorigenic effect of JQ1 is 
strongly associated with MYC downregulation and its targets98,124,125. JQ1 affects MYC 
through inhibition of BRD4 one of the members of BET family, involved in regulation of 
MYC transcription126 (Figure 6 B). The new generation bromodomain inhibitor I-BET has 
been reported to increase cell death in neuroblastoma cells in vitro and to reduce tumor 
burden in vivo in mouse models123,127. Members of the BET (bromodomain and extraterminal 
domain) protein family bind to acetylated lysines on histones in order to recruit the essential 
elements for the transcriptional elongation119.  
A recent report highlighted another approach to target MYC indirectly. The cyclin-dependent 
kinases have a crucial role in regulation of transcription initiation and elongation. The CDK7 
subunit of TFIIH enhances transcriptional initiation, elongation and pause relies through 
phosphorylation of carboxy-terminal domain of RNA polymerase II128. Specific inhibition of 
CDK7 results in significant impact on the transcription of the cell-cycle regulators, including 
MYC111,129 (Figure 6 B). The novel covalent compound THZ1 was discovered and 
characterized as a specific CDK7 inhibitor130. Importantly, THZ1 selectively inhibits growth 
of MYCN-amplified NB cells and demonstrates high efficacy in NB mouse models111  
Recently it was demonstrated that inhibition of Aurora kinase A (Aurora-A) is an effective 
approach of indirect MYC targeting. Aurora kinase is very important for mitotic processes 
and is expressed in many human cancers. Aurora-A forms a complex with MYC and prevents 
its degradation. Downregulation of Aurora kinase A results in MYC degradation and cell 
death131-133. One of the potent Aurora-A inhibitors is small molecule alisertib, which 
demonstrates anti-tumorigenic activity in different types of human malignancies 
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Figure 6. A schematic overview of approaches MYC targeting in cancer. (A) Examples of direct 
strategies to interfere with MYC-MAX dimerization. (B) Examples of indirect MYC targeting via 
regulation of its transcription. 
Importantly, alisertib  has been shown to effective in decreasing proliferation of NB cells 
both in vitro and in vivo134.   
Synthetic lethality is a definition used for increase cell death as consequence of the combined 
alteration in the expression two or more genes, whereas deregulation of only one gene will 
not have the same effect. The analysis of the transcriptome of MYC-overexpressing tumors 
identified genes involved in synthetic lethal relationship with MYC, such as the AMPK-
related kinase 5, BUD31, LDHA and the checkpoint kinase 1 (CK-1)135-137. Targeting 
synthetic lethal interactions of MYC is a promising approach in anti-cancer therapy. 
1.4 CANCER METABOLISM 
Cancer metabolism applies to all modifications in cellular metabolic pathways, which is 
altered in cancer cells compared to the majority of normal cells. Metabolic changes are one of 
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the emerging hallmarks of cancer and involve modifications in glycolysis, OXPHOS and the 
ability of cancer cells to reprogram metabolic processes in order to adapt to high energy 
demand conditions7.  
 
Figure 7. Difference in metabolic pathways between normal and cancer cells. Normal cells 
predominantly breakdown glucose to pyruvate, which is oxidized to CO2 via the Krebs cycle and 
mitochondrial respiration, generating 36 ATP molecules per glucose molecule and 2 ATP molecules 
via anaerobic glycolysis. Many cancer cells metabolize glucose to lactate, producing 4 ATP molecules 
per molecule of glucose.  
1.4.1 Aerobic glycolysis versus oxidative phosphorylation 
Energy production in normal cells depends on mitochondrial oxidative phosphorylation, 
which generates 16 times more adenosine triphosphate (ATP) than glycolysis. Nonetheless, 
cancer cells exhibit increased uptake of glucose for aerobic glycolysis. This phenomena is 
known as the Warburg effect, and was first described in the 1920s by Otto Warburg138. The 
idea was initially based on a hypothesis that mitochondrial dysfunction is common for 
cancer cells. However, during the past decades, numerous scientific reports demonstrated 
that in a majority of cancers, mitochondrial respiration is intact139-142. Cancer includes more 
than 200 types of diseases, which differ by the cell of origin, localization of the primary 
tumors, mutations, age of patients and metastasis. Quite often, the single tumor consists of 
cell populations characterized by different metabolic phenotypes, depending on the stage 
and the microenvironment143. 
Recent studies proposed the idea that the Warburg phenotype is a not the result of 
decreased mitochondrial respiration, but rather of enhanced glycolysis and that inhibition of 
the glycolytic function may induce OXPHOS. Cancer cells have a spare respiratory 
capacity, which may compensate ATP production upon inhibition of aerobic glycolysis. 
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Functional connection between OXPHOS and glycolysis has been established in many 
types of human cancers. For instance, inhibition of LDHA, a member of aerobic glycolysis 
pathway, in cancers cells result in enhanced OXPHOS140. Malignant astrocytoma cells 
exhibit a glycolytic phenotype; however upon glucose deprivation a condition that 
demonstrates a progressively elevated mitochondrial respiration144  
Recent studies highlighted a novel hypothesis - the reverse Warburg effect. The classic 
Warburg effect is the observation that upon hypoxic conditions enhanced glucose uptake 
result in increased level of lactate released to cytoplasm. The reverse Warburg effect 
facilitates cancer cell proliferation via high aerobic glycolysis where lactate is converted to 
pyruvate to support ATP production via OXPHOS in cancer associated macrophages 145,146. 
These results indicate that the connection between mitochondrial OXPHOS and glycolysis 
are cooperative rather, than competitive. 
1.4.2 Metabolic adaptation is a critical factor for cancer aggressiveness 
Metabolic reprogramming is a critical step in cancerogenesis, important not only for cancer 
cell proliferation and biomass synthesis, but also for cell adaptation to the low oxygen level 
and energy demand condition, which is associated with low levels of nutrients. Indeed, one of 
the hallmarks of cancer is metabolic switching to aerobic glycolysis, via overexpressing of 
glucose transporters and increased level of glucose fermented to lactate147. In addition, there 
are more and more evidence about intact and fully functional mitochondria in cancer148. 
Recent studies demonstrate that some cancer cells exhibit metabolic plasticity, where 
OXPHOS and aerobic glycolysis may be reversible149,150. Also, different types of the same 
cancer can be characterized by dissimilar energy metabolism phenotypes139,151. Furthermore, 
the same cancer cells display different metabolic profile depending on the level of energetic 
substrates. For example, short term glucose deprivation, results in elevated mitochondrial 
respiratory capacity in breast cancer cells152. The study of melanoma cells in vivo highlighted 
that metabolic alterations in primary tumors and metastasis differ153. Many solid human 
cancers exhibit a high glycolytic rate, but even then, the majority of ATP (around 30 
molecules) are produced via OXPHOS154,155.  
A deeper understanding of the metabolic plasticity of cancer cells is essential for developing 
new targeting anti-cancer therapy and it can meet great challenges, since the majority of 
novel drug targets were identified during well controlled experiments.  
1.4.3 Fatty acid biosynthesis (Lipogenesis) 
Fatty acids (FA) include several molecule types, which differ in lengths and level of 
saturation of the hydrocarbon chains. The main components of biological membranes are 
cholesterol, phospholipids and glycolipids. FAs form the lipophilic tails of phospholipids and 
glycolipids. Many type of cancer cells display an enhanced rate of de novo lipid synthesis, 
which requires high level of FAs. De novo FA biosynthesis, or lipogenesis, in the mature 
mammalian organism delimited to the several organs, such as liver, the lactating breast and 
adipose tissue156. Elevated rate of FA synthesis in cancer cells may be a consequence of 
energy demand due to high proliferation rate and/or decreased dietary or serum derived lipids 
in the tumor microenvironment. Besides, the activation of FA synthesis can be a result of 
genomic alterations in cancer cells.  
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Lipogenesis plays a very important role during cancerogenesis. FA synthesis not only 
provides the majority of the building blocks for cell growth and serves as a fuel for 
mitochondrial energy production, but is also involved in the regulation of signaling pathways 
related to cell proliferation and metastasis. Oxidation of FAs produces the double the amount 
of energy compered to glucose oxidation. Few scientific reports demonstrate that FA β-
oxidation is essential for the survival of cancer cells upon impaired glycolysis157,158. 
Targeting de novo FA synthesis and oxidation may be used for developing of a promising 
anti-cancer therapeutic strategy.    
1.4.4 Targeting cancer metabolism  
Abnormal metabolic pathways depend highly on available nutrition and are attracted in order 
to target proteins involved in glucose transport (GLUT1 and GLUT4) and glycolytic enzymes 
(HK2, PKM2 and LDHA); in glutaminolysis (GLS); in fatty acid biosynthesis (FASN) and 
fatty acid oxidation (CPT1); the complexes of mitochondrial respiration and APT production. 
Targeting cancer metabolism is one of the most important and novel approach in the clinic, a 
few examples of interfering with energy production pathways in cancer is illustrated in 
(Figure 8) and discussed below. 
The members of the glucose transporter protein family (GLUT) are responsible for glucose 
transport through the plasma membrane and are often found upregulated in many human 
malignancies159,160. Targeting two members of the family, GLUT1 and GLUT4, have been 
successful in in vitro studies. A total block of GLUT1 expression by the small molecule 
WZB117 reduces glucose uptake, reduces cellular proliferation and increases the sensitivity 
of the breast cancer cell to radiotherapy161. Ritonavir, a protease inhibitor, targets GLUT4 and 
decreases viability of glucose dependent multiple myeloma cells162. Treatment with 2-DG, an 
inhibitor of the key glycolytic enzyme HK2 results in cell cycle arrest and significant 
apoptosis in various human cancers163,164. Two more inhibitors of HK2 activity, LND and 3-
BrPA have been shown to have potent potential as anti-cancers agents165-167. LDHA is a 
member of the glycolytic pathway and catalases pyruvate conversion to lactate to facilitate 
cancers cell’s proliferation. Inhibition of LDHA has been proven as a promising strategy for 
hereditary leiomyomatosis and renal cell cancer168,169. 
Glutaminolysis is one of three main fuel sources for mitochondrial respiration and a precursor 
for lipid synthesis170. Also, many cancer cells exhibit “glutamine addiction” and its 
withdrawal results in cell death. GLS is an enzyme essential for glutamine conversion to 
glutamate found to be upregulated in cancers cells. The small molecule BPTES is a GLS 
inhibitor which reduces proliferation rate in cancer cells, for instance in glioblastoma cell 
lines and decreases tumor progression in renal cell cancer and breast carcinomas in vivo171,172. 
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Figure 8.A schematic overview of metabolic pathways in cancer. The red boxes indicate examples 
of chemical compounds, which target key enzymes and interfere with the energetic activity of cancer 
cells.  
The mitochondrial respiratory chain includes several complexes, which facilitate electron 
transport by oxidation-reducing reactions essential for ATP production. Targeting the 
complexes of the electron transport chain (ETC) leads to a slowdown in biomass growth of 
proliferative cells. Metformin decreases liver glucose production and is associated with 
increased insulin sensitivity and weight loss and, importantly it is the most commonly used 
anti-diabetic drug worldwide. Recently, metformin was identified as potent inhibitor of 
mitochondrial respiration and tumor growth suppressor via inhibition of complex I in the 
ETC173,174.  
Elevated levels of lipogenesis and overexpression of fatty acid synthase (FASN) are found in 
different types of cancers175,176. Lipid de novo synthesis is essential for the production of 
building blocks in rapidly proliferating cells and as a source of mitochondrial fuel for ATP 
generation177. Cerulenin is organic compound isolated from Cephalosporium caerulens 
which inhibits FASN activity with anti-tumorigenic effect178,179. Treatment with another 
FASN inhibitor orlistat, an anti-obesity drug, leads to a promising outcome of reduced 
proliferation and decreased angiogenesis in cancer cells180,181. Inhibition of Acetyl-CoA 
carboxylase (ACC), a key enzyme of fatty acid synthesis pathway, by the small molecule 
TOFA results in decreased proliferation of ovarian tumors in vivo181. Also, targeting of ACC 
by the antifungal polyketide soraphen A results in reduced ability to form spheres and 
decreased population of cancer stem cells in breast cancer cell lines182. Recently it has been 
shown that inhibition of β-oxidation results in selective growth inhibition of MYC-
overexpressing triple-negative breast cancer cells in vivo183.  
Overall these results highlight that targeting cancer metabolic pathways is a promising anti-
tumorigenic therapeutic strategy.  
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2 AIMS 
The overall aim of this thesis was to target MYCN and study the biological consequences of 
altered MYCN expression in NB using a combination of different methodological 
approaches.  
The specific aims of the individual papers constituted the present thesis: 
I. To target MYCN-MAX interaction with small chemical molecules previously shown 
to inhibit MYC-MAX heterodimerization and to analyze the biological consequenses 
of MYCN inhibition in NB cells. 
 
II. To investigate the impact of MYCN on energy metabolism in NB using a 
combination of proteomics, transcriptomics and functional data analysis, as well as 
targeting of a neuroblastoma xenograft model in vivo.  
 
III. To explore how the de novo synthesis of FAs is connected to cell differentiation in 
NB cells. 
 
IV. To study the impact of crosstalk between NHRs and the MYC pathway activity 
during NB pathogenesis and diffrentiation. 
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3 RESULTS AND DISCUSSION 
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3.1 PAPER I. MYC INHIBITION INDUCES METABOLIC CHANGES LEADING 
TO ACCUMULATION OF LIPID DROPLETS IN TUMOR CELLS 
The MYC transcription factors are associated with a broad range of human cancers. MYC is 
also an essential factor for initiation and progression of tumorigenesis98. The high-risk NB 
group is characterised by MYCN-amplification and very poor prognosis. Also, MYCN is 
known to inhibit neuronal differentiation and promote the proliferation rate of cancer cells. 
MYCN activity requires its interaction with MAX in the same manner as for c-MYC. 
Targeting MYC is a solid basis for developing a novel anti-cancer therapeutic approach. 
During the last decades, many small molecular weight chemical compounds have been 
identified as direct c-MYC inhibitors, targeting c-MYC-MAX dimerization184,185. In contrast, 
the direct inhibition of MYCN is not well studied. 
 
Figure 9. A graphic summary of paper I. MYCN downregulation in MYCN-amplified neuroblastoma 
cells by 10058-F4 and/or MYCNshRNA results in increased cell death, neuronal differentiation and 
lipid droplet accumulation; targeting MYCN in vivo prolongs survival. 
The aim of paper I was to target the MYCN-MAX complex in MYCN-amplified 
neuroblastoma cells using a small c-MYC binding molecule 10058-F4 in vivo and in vitro. 
Paper I contains several original discoveries summarized in Figure 9. We found that the c-
MYC inhibitor 10058-F4 is also potent against MYCN. This molecule induced cell death and 
reduced cell growth and migration in MNA NB cells. Furthermore, 10058-F4 treatment of 
transgenic Th-MYCN mice, which spontaneously develop NB, significantly prolonged 
survival. MYCN is also a known suppressor of cellular differentiation. We showed that 
10058-F4 treatment is associated with neuronal differentiation, upregulation of the NGF 
receptor TrkA and that NGF treatment potentiates the 10058-F4-induced differentiation in 
MNA NB cells. Importantly, we found that chemical targeting of the MYCN-MAX complex 
or genetically-induced MYCN downregulation using shMYCN resulted in accumulation of 
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lipid droplets in MNA NB cells, suggesting that MYCN is an important regulator of 
metabolism. 
To further analyze the biological consequences of 10058-F4 treatment in MYCN-amplified 
NB, we applied a quantitative proteomics approach using a SK-N-BE(2) NB cell line treated 
with 10058-F4. In parallel, we downregulated the expression of MYCN using short hairpin 
RNA (shRNA) and compared the proteome profiles after MYCN knock-down and after 
10058-F4 treatment. By mass spectrometry based proteomics we demonstrated that MYCN 
as well as c-MYC are the top two transcription factors among the predicted targets of 10058-
F4. Pathway analysis based on the identified proteins demonstrated that the biological effect 
of 10058-F4 treatment highly correlates with the outcome of genetic downregulation of 
MYCN using shRNA. According to Ingenuity prediction analysis, OXPHOS and β-oxidation 
were the most significantly affected canonical pathways. The detailed pathway analysis of the 
generated protein profile highlighted the possible link between MYCN-regulated metabolic 
processes, mitochondrial dysfunction and aggressiveness of NB. 
Importantly, during our experiment with 10058-F4 and MNA NB cells we made an 
unexpected discovery, we found that cells accumulated intracellular lipid droplets. Using 
several different approaches of MYCN targeting, such as the small molecule JQ1 as well as 
MYCN specific shRNA, and several stable transduced cell lines we demonstrated that the lipid 
accumulation is a direct consequence of MYCN inhibition. The analysis of tumor tissue from 
10058-F4 treated animals showed increased lipid accumulation also in vivo. Our data 
suggested that only inhibition of abnormal MYC expression results in lipid accumulation, 
since targeting of physiological MYC level in primary fibroblasts did not show this effect. 
Furthermore, inhibitors against the major metabolic pathways showed that only targeting of 
OXPHOS and β-oxidation, but not of glycolysis-associated enzymes or fatty acid synthase, 
resulted in accumulation of lipid droplets. The targeting of ETC complexes and β-oxidation 
by specific inhibitors resulted in lipid droplet accumulation in NB cells, which supported our 
hypothesis that lipid accumulation is the result of decreased lipid oxidation. This idea also has 
been indirectly supported by our results demonstrating that inhibition of ACC, an enzyme 
involved in de novo FA synthesis, prevented lipid accumulation initiated by 10058-F4. 
However this result could be explained by promoted β-oxidation via increased levels of 
malonyl-CoA. In contrast, targeting of the fatty acid synthesis pathway via the inhibition of 
FASN by cerulenin did not prevent lipid droplet formation. Together our data suggests that 
sustained lipid synthesis and decreased proliferation rate are not major sources of intracellular 
lipid accumulation.  
To estimate the impact of metabolic alterations on patient survival, we analyzed an mRNA 
data set generated from 251 NB patients. Importantly, several genes encoding the metabolic 
proteins downregulated by 10058-F4 correlated with increased survival in NB patients.  
Our study demonstrates that the c-MYC inhibitor 10058-F4 in addition targets the MYCN-
MAX dimer and induces MYCN downregulation. Cell cycle arrest, increased apoptosis and 
differentiation are other outcomes of 10058-F4-induced MYCN inhibition in vitro. 
Furthermore, 10058-F4 treatment prolonged the survival of transgenic Th-MYCN mice and 
delayed tumor growth in a NB xenograft mouse model.  
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Our findings reported in paper I demonstrate that direct targeting of MYCN activity is a 
solid basis for developing of novel promising therapeutic approaches. Also for the first time 
we show a strong connection between MYCN-amplification and altered mitochondrial 
respiration, as well as lipid metabolism. 
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3.2 PAPER II. FATTY ACID-DEPENDENT OXIDATIVE PHOSPHORYLATION IS 
THE MAJOR SOURCE OF ENERGY PRODUCTION IN MYCN-AMPLIFIED 
NEUROBLASTOMA CELLS 
 
Figure 10. A graphic abstract of paper II. MNA NB cells characterised by enhanced aerobic glycolysis 
and fatty acid dependent OXPHOS. Inhibition of β-oxidation potentiates neuronal differentiation in 
NB in vitro and reduces tumour burden in vivo. 
In paper I our findings indicated a strong connection between MYCN and metabolic 
alterations in MNA NB cells. To expand on these previous discoveries, we used a stably 
transduced MNA NB cell line SK-N-BE(2), (BE(2)shMYCN), where MYCN expression was 
downregulated by doxycycline treatment for 24 and 48 hours. Next we applied a mass 
spectrometry based high-resolution quantitative proteomics approach, which allowed us to 
identify more than six thousand proteins186,187. We compared the quantified protein profile 
generated from MNA NB cells with a gene expression data set of 649patients. The analysis of 
protein and gene expression highlighted changes in key enzymes involved in glycolysis (e.g. 
hexokinase 2, HK2; aldolase C, ALDOC, LDHA); β-oxidation (e.g. hydroxyacyl CoA 
dehydrogenase, HADH) in MYCN-amplified NB. We found significantly higher levels in 
MCYN-amplified cell lines, compared to NMNA cells, of components of the Krebs cycle (e.g. 
isocitrate dehydrogenase, IDH2, citrate synthase, CS, oxoglutarate dehydrogenase-like, 
OGDHL), which are essential for cancer progression and are associated with poor patient 
outcome in MYCN-amplified NB. 
Gene set enrichment analysis of the protein profile of BE(2)shMYCN cells showed that a 
large number of proteins which were overexpressed in MNA NB cells are associated with 
mitochondrial respiration (e.g. NDUFS1, SDHB, COX5B, ATP5F2) and mitochondrial 
translation processes (e.g. mitochondrial ribosomal protein S28, MRPS28, mitochondrial 
ribosomal protein S27, MRPS27, glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1, 
QRSL1). Importantly, high expression of these proteins and genes correlated with poor 
prognosis in NB patients. MYCN has been shown to enhance the metabolic activity of 
mitochondria188. We demonstrated that the proteins involved in the mitochondrial biogenesis 
(e. g. mitochondrial fission process 1, MTFP1 and including optic atrophy 1, OPA1), which 
correlated with poor prognosis in NB patients, were upregulated in MNA NB cells.  
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To functionally access the metabolic alteration indicated by data analysis we applied Agilent 
Seahorse XF technology, which provide the information about main energy parameters and 
the metabolic phenotype of the cells. Importantly, the metabolic profiling performed using an 
extracellular flux analyzer showed that MNA NB cells display both enhanced glycolytic and 
respiratory capacity compared to NMNA NB cells. Also, in response to high energy demand 
conditions, such as inhibition of mitochondrial ATP production and/or uncoupling of 
mitochondrial respiration, MNA cells significantly increased the glycolytic rate and the 
mitochondrial capacity. Thus, our functional data demonstrates that MYCN-amplified NB 
cells are characterized by a high energetic metabolic phenotype. 
In addition, we found that MYCN stimulates exogenous fatty acid oxidation (FAO) in NB 
cells, an important metabolic pathway in many types of cancer cells189,190. Based on this 
observation and our data analysis we hypothesized that OXPHOS is the main source of fuel 
in high energetic NB cells. There are three main fuels of mitochondrial respiration: glucose, 
glutamine and fatty acids. We measured the oxygen consumption rate (OCR) in 
BE(2)shMYCN cells in the presence and absence of specific metabolic inhibitors. UK5099, 
which blocks glucose oxidation, via inhibition of mitochondrial pyruvate carrier (MPC), 
etomoxir, which inhibits β-oxidation of FA via targeting of CPT1, and BPTES which inhibits 
CSL1 and suppresses glutaminolysis. The drop in OCR in live cells upon acute etomoxir 
treatment suggests that 75 % of mitochondrial respiratory capacity or OXPHOS is fatty acid 
dependent in BE(2)shMYCN cells.  
We next analyzed the level of the key enzyme of β-oxidation, CPT1 in a neuroblastoma 
patient data set and found that high expression of CPT1 does not depend of MYCN expression 
level. However, high expression of CPT1 correlates with reduced survival of NB patients 
with high MYCN level specifically. Additionally, the obtained data shows that CPT1 
inhibition decreases survival of MNA NB cells, but has non-significant impact on the 
viability of NMNA NB cells. Furthermore, etomoxir treatment potentiated neural 
differentiation in MNA NB cells and reduced tumor burden in vivo. 
During cancerogenesis, cells reprogram their metabolism in order to sustain a high 
proliferation rate. However, very little is known about the metabolic phenotype of MNA NB. 
Understanding of MYCN regulated metabolic processes in NB could provide essential 
information for development of novel therapeutic strategies.  
Taken together, our findings (Fig. 10) provide novel information about MYCN-mediated 
high-energetic metabolic phenotype in NB, which can be a possible mechanism of cancer cell 
survival during NB pathogenesis. We further highlight the crucial role of FAO in 
aggressiveness of MNA NB cells. For the first time, we showed that MNA NB cells display 
fatty acid dependent OXPHOS and that inhibition of fatty acid β-oxidation specifically 
targets MNA NB cells. Most importantly, our in vivo study demonstrated reduced tumor 
burden in a MNA NB xenograft mouse model upon etomoxir treatment.  
In summary, our data suggest that inhibition of fatty acid oxidation in MYCN-amplified 
neuroblastoma may be used for the improvement of therapeutic strategies in one the most 
aggressive childhood cancers. 
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3.3 PAPER III. INDUCTION OF NEURAL DIFFERENTIATION IN NEUROBLASTOMA 
UPON INHIBITION OF DE NOVO FATTY ACID SYNTHESIS 
In paper I we demonstrated that lipid metabolism could be linked to the induction of 
differentiation of NB cells upon MYCN inhibition. The aim of paper III was to study how 
the de novo synthesis of fatty acids is connected to cell differentiation in NB cells. We found 
that this inhibition resulted in several biological effects, such as downregulation of MYCN, 
mitochondrial dysfunction and neural differentiation in neuroblastoma cells. 
 
Figure 11. Graphic abstract of paper III. Targeting of de novo synthesis of fatty acids in 
neuroblastoma cells initiates neural differentiation, leads to MYCN downregulation, increased 
mitochondrial dysfunction and glycolytic capacity of NB cells. 
Reduced overall survival of neuroblastoma patients correlated with high expression of the 
two main enzymes involved in the fatty acid synthesis pathway, acetyl-CoA carboxylase 
(ACC) and fatty acid synthase (FASN). Therefore, we used four different chemical 
compound targeting fatty acid synthesis; cerulenin and orlistat inhibiting FASN and TOFA 
and soraphen A inhibiting ACC. All four small molecules reduced neuroblastoma cell 
viability. In addition, treatment during 7 days resulted in MYCN downregulation and 
induction of neurite outgrowth in MNA NB cells. Furthermore, we showed that targeting 
fatty acid synthesis initiated neurite outgrowth not only in several MNA NB cell lines, but 
also in non-MYCN-amplified NB cells. Inhibition of fatty acid synthesis leads to deprivation 
of intracellular fatty acids. To investigate whether the observed differentiation was a 
consequence of reduced levels of intracellular fatty acids, we treated SK-N-BE(2) cells with 
TOFA or cerulenin in the presence of BSA-coupled palmitate or BSA alone as a control. We 
found that exogenously added palmitate or oleate did not prevent compound-induced 
differentiation or MYCN inhibition in SK-N-BE(2) cells. Furthermore, our results indicated 
that BSA-coupled palmitate or oleate were able to induce neurite outgrowth by itself. Next, 
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we demonstrated that 7 days lack of either glucose or glutamine in the cell culture medium 
did not result in differentiation in SK-N-BE(2) cells and we thus concluded that not all 
nutritional stress conditions induce neural differentiation. 
Previously we demonstrated that MYCN inhibition leads to enhanced mitochondrial 
dysfunction in MNA NB cells. To investigate the functional consequences we performed 
extracellular flux assays to study the effect of targeting of fatty acid synthesis and found that 
inhibition of ACC reduced mitochondrial respiration in MNA NB cells. Besides, our results 
indicated increased glycolytic capacity in NB cells upon inhibition of de novo synthesis of 
FA.  
Anti-cancer therapy is associated with severe side effects, with are consequences of the high 
toxicity for non-transformed cells. Thus therapeutic approaches based on induction of cellular 
differentiation are very promising. After embryonic development, only adipose tissue, liver 
and the lactating mammary gland display lipogenesis, this may reduce the negative impact of 
FA synthesis on targeting of non-cancer cells. Lipogenesis is a well-established hallmark 
associated with many different type of human tumors7. The analysis of a transcriptome data 
set demonstrated a correlation between high expression of two key enzymes of de novo FA 
synthesis, ACC and FASN, and reduced overall survival in NB patients. In paper III we 
showed increased neuronal like outgrowth, as well as an elevated expression of 
differentiation markers upon inhibition of de novo synthesis of fatty acids in both MNA and 
NMNA NB cells. Also, our results indicate that MYCN and c-MYC expressions were 
reduced in several NB cell lines in response to inhibition of lipogenesis. It is very well known 
that high MYCN expression is associated with a non-differentiated tumour phenotype, and 
that MYCN inhibition promotes neurite-outgrowth in NB. In contrast, according to our data 
c-MYC inhibition in NB is not always followed by neuronal differentiation. The reason for 
these differences is not known. 
In paper II we showed that FA is the main source of energy in NB cells. Therefore, 
increased neuronal differentiation may be the result of nutritional stress. In paper III we 
therefore studied the effect of glucose and/or glutamine withdrawal in NB cells and 
demonstrated that their deprivation did not initiate morphological changes in NB cells. 
Furthermore, the effect of FA synthesis inhibition was neither reversed by exogenously added 
palmitate nor by oleate. The findings reported in paper III indicate that inhibition of fatty 
acid synthesis in NB cells results in neuronal differentiation, but this effect was not the 
consequence of fatty acid withdrawal per se. 
Previously we reported that MYCN downregulation in NB cells results not only in neuronal 
differentiation, but also in enhanced mitochondrial dysfunction. Moreover, the data presented 
in paper II highlighted that FAs are the main the source for mitochondrial energy 
production. In paper III we then demonstrated that neural differentiation of NB cells is 
connected not only with MYCN downregulation, but also with mitochondrial biogenesis 
(Figure 11). The functional assays supported our idea showing that targeting de novo 
synthesis of fatty acids in vitro reduces the mitochondrial respiratory capacity in NB. 
Together, our study shows that targeting of the fatty acid synthesis pathway in NB may be the 
basis for development of novel therapeutic approaches for NB treatment. 
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3.4 PAPER IV. REGULATION OF NUCLEAR HORMONE RECEPTORS BY 
MYCN DRIVEN MIRNAS IMPACTS NEURAL DIFFERENTIATION AND 
SURVIVAL IN NEUROBLASTOMA PATIENTS 
Figure 12. Graphical abstract of paper IV. MYCN-regulated miR-17~92 cluster suppresses neural 
differentiation via targeting of members of nuclear hormone receptors family (NHR). Combination of 
MYCN inhibition and glucocorticoid activation promote neural differentiation and reduce tumor 
burden. (Reprinted from Ribeiro et al, Cell reports 2016 with a kind permission from Elsevier). 
We previously demonstrated that NB differentiation is inhibited by the MYCN-regulated 
miR-17~92 cluster through downregulation of estrogen receptor alpha14. Given that the NHR 
family has been associated with differentiation in cells of neural origin, we hypothesized that 
several other NHRs also could play a role in the development and/or progression of 
neuroblastoma. Thus, the aim of Paper IV was to investigate the regulation of NHRs in 
MYCN-driven NB. We first applied an in silico prediction analysis to identify miR-17~92 
associated binding sites in the 3’-UTRs of all NHR family members. We found that miR-
17~92 target sites are disproportionally enriched in the 3’-UTRs of the NHR superfamily. 
Furthermore, our analysis indicated that high expression of several NHRs correlated with low 
levels of MYCN and with increased survival in NB patients. Next, using RT-PCR and 
TaqMan based arrays we evaluated the expression level of NHR family members in a NB cell 
line stably expressing miR-17~92 cluster. We found that the genes encoding the 
glucocorticoid receptor (GR), peroxisome proliferator-activated receptor beta delta (PPARD), 
liver X receptor B (LXRB), and nuclear receptor related 1 (NURR1) were downregulated. 
Using luciferase reporter constructs containing the wildtype or mutated 3’-UTRs from the 
NHR-encoding genes; we verified that these are the direct targets of miR-17~92. We 
furthermore found that the nuclear receptor coactivator 1 (NCOA1) is a direct target of miR-
18a, and thus that further NHRs may be targeted via NCOA1. 
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The analysis of one mRNA data set from 649 NB patients highlighted the association of high 
expression of NHRs with increased overall survival in NB patients. Besides, we demonstrated 
the reverse correlation between the genes encoding the NHRs and MYCN levels.  
Since GR was the most downregulated member of the NHR family in MNA NB patients we 
focused on this protein. Analysis of cell lines where the MYCN or miR-17~92 expression 
could be genetically modulated revealed that GR expression in NB cells is suppressed by 
MYCN as well as by miR-17~92. Furthermore, we demonstrated that activation of GR 
signaling by its ligand dexamethasone (DEX) enhances neural differentiation and expression 
of differentiation markers in NB cells.  
We next investigated the significance of MYCN-mediated GR regulation in vivo. Th-MYCN 
mice were treated with the small molecule MYC inhibitor 10058-F4 during 6 days. Inhibition 
of MYCN led to a two-fold increase in the number of GR positive cells compared to 
untreated tumors.  
To study the functional role of GR in neuroblastoma, we treated SK-N-BE(2) MNA NB cells 
for 6 days with DEX, 10058-F4 and the combination of the MYC inhibitor and DEX (10058-
F4+DEX), where ligand was added after 72 hours of 10058-F4 pretreatment. Incubation with 
10058-F4 resulted in decreased MYCN expression and increased GR level in SK-N-BE(2) 
cells. We did not detect changes in MYCN expression upon DEX treatment alone, however 
the combination treatment potentiated the decrease in MYCN level initiated by 10058-F4. 
Also, DEX or combined 10058-F4+DEX treatment suppressed GR expression. Furthermore, 
10058-F4 alone or in combination with DEX promoted expression of the differentiation 
marker TrkA. Moreover, combination treatment increased the level of the apoptosis marker 
cleaved poly (ADP-ribose) polymerase (PARP) and decreased the expression of proliferating 
cell nuclear anti-gene (PCNA). 
To study the impact of GR on cellular differentiation in NB in another model, we applied our 
differentiation scheme to tumor-spheres cells derived from Th-MYCN mice. We obtained 
similar results as in SK-N-BE(2) cells. 10058-F4 treatment downregulated MYCN expression 
and increased GR levels while incubation of Th-MYCN cells with DEX resulted in MYCN 
decrease and combination treatment potentiated this effect. Furthermore, all treatments 
involved in our approach resulted in reduced expression of miR-17, miR-18a and miR-19a. 
We generated stably expressing GR MNA NB cell lines for further understanding of GR 
functions in NB pathogenesis. Activation of GR in these cells resulted in decreased MYCN 
levels as well as elevated expression of the TH neural differentiation marker. 
Next, we employed our treatment scheme to in vivo experiments using a NB xenograft model 
using the highly aggressive SK-N-BE(2) cells. Indeed, MYCN inhibition followed by 
activation of GR signaling resulted in a significant reduction in tumor burden. 
The data reported in paper IV highlighted the importance of the NHR family as targets of the 
miR-17~92 cluster for neuroblastoma pathogenesis. Our results demonstrate that increased 
expression of GR not only promoted neural differentiation, but also decreased MYCN 
expression in MNA NB cells. Furthermore, GR signaling resulted in upregulation of 
canonical differentiation markers in neuroblastoma.  
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Taken together our findings summarized in Figure 12 reveal MYCN-mediated deregulation 
of NHRs through the miR-17~92 cluster as a critical factor in NB tumorigenesis. Importantly, 
these recent findings can contribute to the development of novel therapies for MYCN-
amplified NB. 
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4 CONCLUSION AND OUTLOOK 
MYCN-amplification is associated with an aggressive type of childhood NB and with poor 
outcome for patients. We are aiming to improve the biological understanding of this disease, 
which today is the major cause of death from cancer in children. Our recent results included 
in this thesis show that it is feasible and possible to directly target the MYCN-MAX dimer. In 
addition, these findings support the idea of developing an anti-cancer therapy based on 
targeting of MYCN-regulated metabolic processes essential for cancer cell survival and 
proliferation in MYCN-amplified NB cells.  
Targeting of MYCN and understanding of the biological outcome of MYCN downregulation 
in NB is a very challenging goal in cancer research. We reported in paper I that a small 
chemical molecule, 10058-F4, previously identified as a c-MYC inhibitor also successfully 
targets MYCN-MAX dimerization, which in turn results in MYCN downregulation, 
increased neuronal differentiation in vitro and prolonged survival in vivo. We further 
demonstrated that is possible to achieve MYCN inhibition by treatment with a low-molecular 
weight compound. Besides, we detected intracellular lipid accumulation as a direct 
consequence of MYCN downregulation accompanied by mitochondrial dysfunction in 
MYCN-amplified NB cells. Together, our findings demonstrated the importance of MYCN-
mediated metabolic processes in NB. 
Paper II and paper III are logical continuations of paper I. Indeed, our data demonstrates 
that the aggressiveness of MYCN-amplified NB may be driven by a high-energetic metabolic 
phenotype in this type of cancer. In paper II we reported that MYCN not only maintains a 
high glycolysis rate, but also enhances OXPHOS in MNA NB. Using analysis of 
transcriptome data, we demonstrated that high expression of key metabolic enzymes 
correlated with MYCN-amplification in NB patients. Furthermore, we showed intact 
mitochondria and energy production via OXPHOS is critical for MNA NB survival. 
Furthermore, in paper II we established that mitochondrial respiration is highly dependent 
on fatty acids in MNA NB cells. Importantly, our data suggests that targeting of the main 
source of mitochondrial respiration - fatty acid oxidation - results in enhanced neuronal 
differentiation in vitro and reduced tumor burden in vivo.  
Our data clearly demonstrates that MYCN-mediated metabolic alterations are one of the most 
prominent features of MNA NB cells. In paper III we focused on the investigating the 
possible connection between the metabolic and differentiation processes in these cells. Our 
results showed that inhibition of de novo synthesis of fatty acids resulted in mitochondrial 
dysfunction and in neuronal outgrowth in NB cells. Moreover, we observed MYCN 
inhibition upon reduced lipogenesis.  
In paper IV we demonstrated that MYCN suppresses neuronal differentiation in NB via 
upregulation of miR-17~92 cluster, which targets NHRs. Specifically, MYCN inhibition 
results in increased levels of GR and promoted expression of differentiation markers in NB. 
Inhibition of MYCN was followed by increased GR expression and reduced tumor burden in 
vivo. 
 44 
In conclusion, taken together our findings using small MYC-inhibiting molecules and 
metabolic alterations associated with MYCN in NB may be of importance for the 
development of new treatment options for high risk NB patients. 
The detailed understanding of metabolic processes and the targeting of metabolic enzymes to 
regulate specific bioenergetic functions in cancer cells is critical for successful clinical 
outcome. Several scientific reports suggest that cancer aggressiveness may be associated with 
metabolic reprograming and/or metabolic adaptation. Our data identified MYCN as a main 
regulator of MNA NB metabolism, which enhances energetic parameters in NB. Moreover 
we demonstrated an importance of mitochondrial biogenesis in MNA NB. Since normal cells 
relay on OXPHOS energy production, direct targeting of mitochondria may be very toxic. 
Using selective inhibitors for the main fuel sources in cancer cells as well as MYCN 
inhibition which result in decreased metabolic activity and decreased cell proliferation may 
therefore be more specific for cancer cells.  
Our data suggests that the balance between the key enzymes involved in FA synthesis has a 
significant impact on NB cells. Further investigation of the connection between the induced 
metabolic alterations and neuronal differentiation in NB is needed. 
Recently, it was shown that the miR-17~92 cluster is a global regulator of cancer metabolism. 
In our previous publication, we demonstrated that this cluster is involved in regulation of 
neuronal differentiation in MNA NB. However, the role of the cluster in NB metabolism 
remains unclear and needs further studies. 
Increased knowledge about the impact of MYCN on metabolic alterations, the detoxification 
system and mitochondrial processes will provide not only information about the significance 
of MYCN for tumor development, but also expand the knowledge about cancer cell 
resistance and survival. Together this will provide new knowledge that can form the basis for 
novel therapeutic approaches not only for MYCN-amplified NB but also for other tumors as 
MYC is a global oncogene involved in a majority of human cancer.  
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